Markets

Depression biotech gets a sweetener: Cerecor adds warrants ahead of $27 million IPO

Cerecor, which is developing a novel adjunct therapy for major depressive disorder, revised terms for its IPO on Thursday.

The Baltimore, MD-based company had originally planned to raise $27 million by offering 4.23 million shares at a price range of $6 to $7. At the midpoint of the range, it would have commanded a market value of $58 million.

In its latest amendment, Cerecor disclosed that it still plans to raise $27 million, but by offering 4.23 million units at the same range. Each unit will consist of one common share, one Class A warrant immediately exercisable for one share at $4.55 and one Class B warrant immediately exercisable for one-half of one share at an exercise price of $3.90 per full share. Accounting for the dilutive warrants, Cerecor would command a fully diluted market value of $71 million at the midpoint.

Cerecor, which was founded in 2011, plans to list its units on the Nasdaq under the symbol CERCU. The units, common shares ( CERC ), Class A warrants (CERCW) and Class B warrants (CERCZ) will begin to trade separately on the 60th day following the offering. Cerecor initially filed confidentially on December 20, 2013. Maxim Group is the sole bookrunner on the deal. It is expected to price during the week of October 5, 2015.

The article Depression biotech gets a sweetener: Cerecor adds warrants ahead of $27 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CERC

Other Topics

IPOs

Latest Markets Videos

    Renaissance Capital

    Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

    Learn More